Spots Global Cancer Trial Database for monoclonal gammopathy of undetermined significance (mgus)
Every month we try and update this database with for monoclonal gammopathy of undetermined significance (mgus) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss | NCT03951220 | Myeloma Monoclonal Gamm... Smouldering Mye... | Diffusion Weigh... DXA scan Bloods and urin... | 18 Years - 99 Years | Oxford University Hospitals NHS Trust | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | NCT05283993 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm... | No intervention | - | Peking University First Hospital | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | NCT05283993 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm... | No intervention | - | Peking University First Hospital | |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | NCT02269592 | Monoclonal Gamm... Chronic Lymphoc... Myelodysplastic... Hematological M... B-cell Malignan... Myelodysplastic... IgG Monoclonal ... Smoldering Mult... Waldenstrom Mac... | 18 Years - | Dana-Farber Cancer Institute | ||
| Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | NCT04731844 | Prostate Cancer Multiple Myelom... Smoldering Mult... Monoclonal Gamm... | Curcumin plus P... | 18 Years - | University of Rochester | |
| B-Cell Hematologic Malignancy Vaccination Registry | NCT02298816 | Monoclonal Gamm... Multiple Myelom... Waldenstrom Mac... Lymphocytosis Lymphoma, Non-H... B-Cell Chronic ... Hematological M... | - | Aurora Health Care | ||
| B-Cell Hematologic Malignancy Vaccination Registry | NCT02298816 | Monoclonal Gamm... Multiple Myelom... Waldenstrom Mac... Lymphocytosis Lymphoma, Non-H... B-Cell Chronic ... Hematological M... | - | Aurora Health Care | ||
| Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | NCT04731844 | Prostate Cancer Multiple Myelom... Smoldering Mult... Monoclonal Gamm... | Curcumin plus P... | 18 Years - | University of Rochester | |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | NCT06140524 | Monoclonal Gamm... Smoldering Mult... | Linvoseltamab | 18 Years - | Regeneron Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
